Current Treatment Options for DLBCL Besides R-CHOP Chemotherapy
Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Jason Westin, MD, MS, FACP, director, Lymphoma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, and associate professor at The University of Texas MD Anderson Cancer Center, discusses the current treatment options for patients with diffuse large B-cell lymphoma (DLBCL) that are available besides rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP).
For patients with DLBCL, the other frontline option is a modified chemotherapy regimen, such as dose-adjusted R-EPOCH. In addition, the combination of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) or cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate (CODOX-M) are also modified versions of R-CHOP that are available for patients with DLBCL.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Zilovertamab Vedotin/R-CHP Elicits High Complete Response Rate in DLBCL
Published: December 8th 2024 | Updated: December 8th 2024The addition of zilovertamab vedotin to R-CHP (cyclophosphamide, doxorubicin, prednisone, rituximab) resulted in a 100% complete response rate in patients with previously untreated DLBCL.
Read More
